- Home
- CMMB vs FTFT Comparison
CMMB vs FTFT Comparison
Compare CMMB & FTFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMMB | FTFT |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 7.5M |
| IPO Year | 2023 | 2008 |
Fundamental Metrics
Financial Performance| Metric | CMMB | FTFT |
|---|---|---|
| Price | $1.85 | $1.39 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | ★ 69.1K | 8.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | 31.14 |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $2,158,125.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.75 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $0.17 |
| 52 Week High | $3.86 | $4.03 |
Technical Indicators
Market Signals| Indicator | CMMB | FTFT |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 41.53 |
| Support Level | $1.57 | $1.29 |
| Resistance Level | $2.80 | $1.60 |
| Average True Range (ATR) | 0.19 | 0.11 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 62.51 | 11.83 |
Price Performance
Historical ComparisonAbout CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.